Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 6/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6000924 | 0.89 | RAB9A (0.42) | RAB9AMAPTPOLBTSHRNPC1 | |
| SCHEMBL6002863 | 0.85 | MAPT (0.32) | MAPTRXFP1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL20094718 | 0.81 | RAB9A (0.48) | RAB9AMAPTPOLBTSHRNPC1 | |
| SCHEMBL5069175 | 0.77 | RAB9A (0.49) | RAB9AMAPTPOLBTSHRNPC1 | |
| SCHEMBL6002858 | 0.75 | CA12 (0.37) | MAPTKMT2APKM | |
| SCHEMBL642545 | 0.72 | CYP3A4 (0.50) | MAPTKMT2APKMKDM4E | |
| SCHEMBL28619570 | 0.69 | MAPT (0.46) | RAB9AMAPTPOLBTSHRNPC1 | |
| SCHEMBL20554137 | 0.68 | CYP3A4 (0.51) | MAPTTSHRKMT2APKM | |
| SCHEMBL20031462 | 0.68 | ALDH1A1 (0.46) | RAB9AMAPTNPC1RXFP1KMT2A | |
| SCHEMBL5069164 | 0.68 | CA12 (0.58) | RAB9ATSHRKMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060229286-A1 | Compound inhibiting dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229286-A1 | Compound inhibiting dipeptidyl peptidase IV | DPP4, DPP3, DPP7 | RAB9A 3667/4885MAPT 4195/4885POLB 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.